Day One Biopharmaceuticals Holding Co LLC Contracts & Agreements
27 Contracts & Agreements
- Business Finance (12 contracts)
- Business Operations (1)
- Human Resources (4)
- Intellectual Property (6)
- Real Estate (2)
- Uncategorized (2)
- Exclusive License Agreement by and between Day One Biopharmaceuticals, Inc. and Ipsen Pharma SAS dated July 23, 2024 (Filed With SEC on October 30, 2024)
- Exclusive License Agreement by and between MabCare Therapeutics and Day One Biopharmaceuticals, Inc. dated June 17, 2024 (Filed With SEC on August 2, 2024)
- Asset Purchase Agreement, dated May 29, 2024 (Filed With SEC on August 2, 2024)
- Form of Registration Rights Agreement (Filed With SEC on July 30, 2024)
- Form of Securities Purchase Agreement (Filed With SEC on July 30, 2024)
- Form of Pre-Funded Warrant (Filed With SEC on July 30, 2024)
- Amendment No. 1 to the License Agreement for RAF, dated March 4, 2024, by and between Day One Biopharmaceuticals, Inc. and Sunesis Pharmaceuticals, Inc (Filed With SEC on March 7, 2024)
- Underwriting Agreement, dated June 6, 2023 (Filed With SEC on June 7, 2023)
- Office Lease between Aircraft Technical Publishers, a California corporation and Day One Biopharmaceuticals, Inc. dated April 1, 2022 (Filed With SEC on August 4, 2022)
- Underwriting Agreement, dated June 14, 2022 (Filed With SEC on June 16, 2022)
- Form of Change in Control and Severance Agreement (Filed With SEC on March 7, 2022)
- Description of Registrants Securities (Filed With SEC on March 7, 2022)
- 2021 Employee Stock Purchase Plan and forms of award agreements (Filed With SEC on May 24, 2021)
- Employment Offer Letter, dated May 19, 2020, by and between the Registrant and Dr. Jeremy Bender (Filed With SEC on May 24, 2021)
- 2021 Equity Incentive Plan and forms of award agreements (Filed With SEC on May 24, 2021)
- Form of Common Stock Certificate (Filed With SEC on May 24, 2021)
- Form of Underwriting Agreement (Filed With SEC on May 24, 2021)
- Form of Plan of Conversion (Filed With SEC on May 4, 2021)
- Stock Exchange Agreement, dated May 4, 2021, by and between Day One BioPharmaceuticals Holding Co., LLC and Millennium Pharmaceuticals, Inc (Filed With SEC on May 4, 2021)
- License Agreement, dated February 10, 2021, by and between Merck KGaA, Darmstadt, Germany and Day One Biopharmaceuticals, Inc (Filed With SEC on May 4, 2021)
- License Agreement for RAF, effective as of December 16, 2019, by and between Sunesis Pharmaceuticals, Inc. and DOT Therapeutics-1, Inc (Filed With SEC on May 4, 2021)
- Asset Transfer and License Agreement, effective as of December 16, 2019, by and between DOT Therapeutics-1, Inc. and Millennium Pharmaceuticals, Inc (Filed With SEC on May 4, 2021)
- Office Lease, dated February 8, 2020, by and between Kashiwa Fudosan America, Inc. and Day One Therapeutics, Inc (Filed With SEC on May 4, 2021)
- 2021 Employee Stock Purchase Plan and forms of award agreements (Filed With SEC on May 4, 2021)
- 2021 Equity Incentive Plan and forms of award agreements (Filed With SEC on May 4, 2021)
- Form of Indemnification Agreement with directors and officers (Filed With SEC on May 4, 2021)
- Amended and Restated Investors Rights Agreement, dated February 1, 2021, by and among the Registrant and certain of its stockholders (Filed With SEC on May 4, 2021)
